Table 1 Demographic and Clinical Characteristicsa
From: Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ)
Randomization Groups | |||
|---|---|---|---|
Total Evaluable Sample N = 310 | Dulaglutide Device First N = 155 | Semaglutide Device First N = 155 | |
Age, years (mean, SD) | 60.0 (10.86) | 60.5 (11.43) | 59.5 (10.28) |
Minimum-maximum | (30–86) | (34–86) | (30–83) |
Gender, female (n, %) | 150 (48.4%) | 68 (43.9%) | 82 (52.9%) |
Ethnicity: Hispanic or Latino (n, %)b | 39 (12.6%) | 19 (12.3%) | 20 (12.9%) |
Racial background (n, %) | |||
Asian | 10 (3.2%) | 7 (4.5%) | 3 (1.9%) |
Black or African American | 105 (33.9%) | 52 (33.5%) | 53 (34.2%) |
White | 155 (50.0%) | 79 (51.0%) | 76 (49.0%) |
Otherc | 40 (12.9%) | 17 (11.0%) | 23 (14.8%) |
Employment status (n, %) | |||
Full-time work | 106 (34.2%) | 57 (36.8%) | 49 (31.6%) |
Part-time work | 43 (13.9%) | 17 (11.0%) | 26 (16.8%) |
Retired | 98 (31.6%) | 55 (35.5%) | 43 (27.7%) |
Disabled | 39 (12.6%) | 18 (11.6%) | 21 (13.5%) |
Otherd | 24 (7.7%) | 8 (5.2%) | 16 (10.3%) |
Education level (n, %) | |||
No college degree | 201 (64.8%) | 102 (65.8%) | 99 (63.9%) |
College degree | 109 (35.2%) | 53 (34.2%) | 56 (36.1%) |
Type of clinical recruitment site | |||
General practice | 242 (78.1%) | 120 (77.4%) | 122 (78.7%) |
Specialist | 68 (21.9%) | 35 (22.6%) | 33 (21.3%) |
US geographic regione | |||
Northeast | 10 (3.2%) | 6 (3.9%) | 4 (2.6%) |
Midwest | 62 (20.0%) | 29 (18.7%) | 33 (21.3%) |
South | 203 (65.5%) | 102 (65.8%) | 101 (65.2%) |
West | 35 (11.3%) | 18 (11.6%) | 17 (11.0%) |
Duration of diabetes (mean years, SD) | 8.06 (6.76) | 8.52 (7.03) | 7.61 (6.47) |
Current oral medication to treat T2DM (n, %) | |||
Sulfonylureas | 74 (23.9%) | 40 (25.8%) | 34 (21.9%) |
Biguanide | 257 (82.9%) | 130 (83.9%) | 127 (81.9%) |
DPP-4 inhibitors | 20 (6.5%) | 11 (7.1%) | 9 (5.8%) |
SGLT2 inhibitors | 17 (5.5%) | 10 (6.5%) | 7 (4.5%) |
Thiazolidinediones | 7 (2.3%) | 5 (3.2%) | 2 (1.3%) |
Combination pills | 35 (11.3%) | 15 (9.7%) | 20 (12.9%) |
Most recent HbA1c value | |||
Participants with HbA1c data (n, %) | 304 (98.1%) | 150 (48.4%) | 154 (49.7%) |
Mean (SD) | 7.29 (1.42) | 7.24 (1.35) | 7.34 (1.48) |